How to Survive COVID‐19 Even If the Vaccine Fails
暂无分享,去创建一个
[1] M. M. van der Eerden,et al. Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.
[2] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[3] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[4] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[5] E. Fish,et al. Interferon-α2b Treatment for COVID-19 , 2020, Frontiers in Immunology.
[6] Victor G. Puelles,et al. Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.
[7] Malik Peiris,et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.
[8] J. Shaman,et al. Direct Observation of Repeated Infections With Endemic Coronaviruses , 2020, medRxiv.
[9] D. Cyranoski. Profile of a killer: the complex biology powering the coronavirus pandemic , 2020, Nature.
[10] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.
[11] D. Montefiori,et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 , 2020, bioRxiv.
[12] X. Tang,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[13] Hans Clevers,et al. SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.
[14] F. Rieux-Laucat,et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients , 2020, medRxiv.
[15] U. Reimer,et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors , 2020, medRxiv.
[16] A. Iwasaki,et al. The potential danger of suboptimal antibody responses in COVID-19 , 2020, Nature Reviews Immunology.
[17] D. Bernstein,et al. COVID-19 Presenting as Acute Hepatitis , 2020, The American journal of gastroenterology.
[18] Jing Xu,et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study , 2020, Journal of Hepatology.
[19] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[20] Andrew Rambaut,et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic , 2020, Nature Microbiology.
[21] Y. Wen,et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.
[22] J. Hindson. COVID-19: faecal–oral transmission? , 2020, Nature Reviews Gastroenterology & Hepatology.
[23] E. Holmes,et al. The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.
[24] R. Lu,et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.
[25] R. Atun,et al. The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 Countries , 2020 .
[26] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[27] Chuan Qin,et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. , 2019, JCI insight.
[28] S. Saab,et al. Toward the elimination of hepatitis C in the United States , 2018, Hepatology.
[29] M. Phipps,et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.
[30] S. Perlman,et al. Middle East respiratory syndrome vaccines , 2016, International Journal of Infectious Diseases.
[31] Jing Xie,et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.
[32] Fu-Tong Liu,et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.
[33] L. Enjuanes,et al. Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread. , 2012, The Journal of general virology.
[34] Hong Yang,et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study , 2011, The Journal of Immunology.
[35] S. Günther,et al. Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections , 2010, Journal of Virology.
[36] A. Osterhaus,et al. Vaccine-induced enhancement of viral infections , 2008, Vaccine.
[37] P. Masters,et al. The Molecular Biology of Coronaviruses , 2006, Advances in Virus Research.
[38] R. Koup,et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients , 2006, Clinical Immunology.
[39] Ching-lung Lai,et al. SARS‐associated viral hepatitis caused by a novel coronavirus: Report of three cases , 2004, Hepatology.
[40] J. Dennis,et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.
[41] M. Hancock,et al. Treatment of acute lymphoblastic leukemia : 30 years' experience at St. Jude Children's Research Hospital , 1993 .
[42] D. Tyrrell,et al. The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.
[43] H. Vennema,et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization , 1990, Journal of virology.
[44] J. Fox,et al. RISES IN TITERS OF ANTIBODY TO HUMAN CORONA VIRUSES OC43 AND 229E IN SEATTLE FAMILIES DURING 1975–1979 , 1986, American journal of epidemiology.